PURE Bioscience Announces Closing of Public Offering of 4.3 Million Shares of Common Stock, Including the Underwriter's Over-Allotment Option

Published: Sep 18, 2012

SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the closing of an underwritten public offering of 3,784,000 shares of its common stock at an offering price of $1.10 per share. In addition, the Underwriter has exercised the over-allotment option, and purchased an additional 557,615 shares of common stock to cover over-allotments. The gross proceeds to PURE from the offering, including the exercise of the over-allotment option, were approximately $4,775,777, before deducting the underwriting discount and other offering expenses payable by PURE.

Back to news